ADMA Biologics Inc <ADMA.OQ> expected to post earnings of 15 cents a share - Earnings Preview
ADMA Biologics Inc ADMA.OQ ADMA.O is expected to show a rise in quarterly revenue when it reports results on March 3 for the period ending December 31 2024
The Ramsey New Jersey-based company is expected to report a 52.6% increase in revenue to $112.8 million from $73.9 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for ADMA Biologics Inc is for earnings of 15 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for ADMA Biologics Inc is $25.00, above its last closing price of $15.44.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | 0.13 | 0.13 | 0.15 | Beat | 15.4 |
Jun. 30 2024 | 0.08 | 0.08 | 0.13 | Beat | 62.5 |
Mar. 31 2024 | 0.06 | 0.06 | 0.08 | Beat | 45.5 |
Dec. 31 2023 | 0.03 | 0.03 | -0.08 | Missed | -420 |
Sep. 30 2023 | 0.00 | -0.01 | 0.01 | Beat | 233.3 |
Jun. 30 2023 | -0.02 | -0.02 | -0.03 | Missed | -20 |
Mar. 31 2023 | -0.04 | -0.04 | -0.03 | Beat | 29.4 |
Dec. 31 2022 | -0.06 | -0.06 | -0.06 | Met | 4 |
This summary was machine generated February 28 at 21:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
[U.S. IPO] BNPL Firm Klarna Set for IPO, Valuation Only Half That of Affirm Amid High Demand
TradingKey - Swedish fintech firm Klarna, is set to finalize its IPO pricing on Tuesday evening, as it continues to gain fame for its "Buy Now, Pay Later" (BNPL) services. The company is valued at just $14 billion, which is half of its U.S. rival Affirm Holdings' valuation, yet it is attracting stro.jpg)
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%
U.S. August Nonfarm Payroll Preview: Risks Focus on Downward Revision of July Data
TradingKey - On 5 September 2025, the U.S. Department of Labour will release the August Non-Farm Payrolls report. The market widely expects August to see an addition of 75,000 non-farm jobs, roughly in line with July’s 73,000.
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks ahead
US NFP Nightmares Preview: A Tiny August Revision, a Huge Annual Benchmark Cut And a Fed in Flux
TradingKey - Wall Street expects modest job growth and a rebound in the unemployment rate in August NFP report, a balanced outcome that could support a September rate cut. However, a massive downward revision — a “terrifying scene” — and anomalies on the supply side could plunge the Fed into deeper (1).jpg)
